Samsung Highlights New Biosimilar Switching Data At EULAR
This article was originally published in PharmAsia News
Executive Summary
South Korea's Samsung Bioepis, which is tapping the US market with its infliximab biosimilar, has presented new clinical switching data for its etanercept product Benepali, its infliximab biosimilar Flixabi, and SB5, an investigational version of adalimumab, at the annual European Congress on Rheumatology.
You may also be interested in...
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.